Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)

by | Apr 13, 2026 | Clinical Trials | 0 comments

​ Conditions: Recurrent Adenoid Cystic Carcinoma; Adenoid Cystic Carcinoma Metastatic; Papillary Thyroid Carcinoma

Interventions: Drug: Sacituzumab Tirumotecan

Sponsors: National Cancer Centre, Singapore; Merck Sharp & Dohme LLC; National Cancer Center, Japan

Not yet recruiting Conditions: Recurrent Adenoid Cystic Carcinoma; Adenoid Cystic Carcinoma Metastatic; Papillary Thyroid Carcinoma
Interventions: Drug: Sacituzumab Tirumotecan
Sponsors: National Cancer Centre, Singapore; Merck Sharp & Dohme LLC; National Cancer Center, Japan
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *